Surgalign Holdings, Inc. Logo

Surgalign Holdings, Inc.

SRGA

(2.5)
Stock Price

0,18 USD

-66.16% ROA

416.3% ROE

-0.05x PER

Market Cap.

1.679.653,00 USD

-54.1% DER

0% Yield

-77.91% NPM

Surgalign Holdings, Inc. Stock Analysis

Surgalign Holdings, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Surgalign Holdings, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (1763.89%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

The stock's low PBV ratio (-0.08x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-54%), which means it has a small amount of debt compared to the ownership it holds

4 Net Profit Growth

Throughout the past five years, this company has consistently experienced net profit growth, indicating a strong financial performance and making it an attractive investment prospect.

5 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

6 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

7 ROA

The stock's ROA (-74.56%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Surgalign Holdings, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Surgalign Holdings, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Surgalign Holdings, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Surgalign Holdings, Inc. Revenue
Year Revenue Growth
1999 33.025.987
2000 122.503.000 73.04%
2001 140.726.000 12.95%
2002 118.490.000 -18.77%
2003 75.510.000 -56.92%
2004 92.703.000 18.55%
2005 75.199.000 -23.28%
2006 73.970.000 -1.66%
2007 94.207.000 21.48%
2008 146.635.000 35.75%
2009 164.527.000 10.87%
2010 166.171.000 0.99%
2011 169.316.000 1.86%
2012 178.113.000 4.94%
2013 197.979.000 10.03%
2014 262.810.000 24.67%
2015 282.293.000 6.9%
2016 272.865.000 -3.46%
2017 279.563.000 2.4%
2018 280.855.000 0.46%
2019 117.423.000 -139.18%
2020 101.749.000 -15.4%
2021 90.500.000 -12.43%
2022 81.979.000 -10.39%
2023 66.992.000 -22.37%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Surgalign Holdings, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1999 1.675.019
2000 2.392.000 29.97%
2001 2.631.000 9.08%
2002 2.460.000 -6.95%
2003 2.441.000 -0.78%
2004 3.838.000 36.4%
2005 5.003.000 23.29%
2006 5.403.000 7.4%
2007 5.190.000 -4.1%
2008 8.143.000 36.26%
2009 8.899.000 8.5%
2010 9.435.000 5.68%
2011 9.806.000 3.78%
2012 12.231.000 19.83%
2013 15.241.000 19.75%
2014 15.536.000 1.9%
2015 15.065.000 -3.13%
2016 16.090.000 6.37%
2017 13.375.000 -20.3%
2018 14.410.000 7.18%
2019 16.836.000 14.41%
2020 11.947.000 -40.92%
2021 13.888.000 13.98%
2022 15.736.000 11.74%
2023 11.620.000 -35.42%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Surgalign Holdings, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1999 0
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 20.000 100%
2013 0 0%
2014 4.798.000 100%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 104.668.000 100%
2022 95.888.000 -9.16%
2023 84.508.000 -13.47%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Surgalign Holdings, Inc. EBITDA
Year EBITDA Growth
1999 2.916.725
2000 9.459.000 69.16%
2001 -6.841.000 238.27%
2002 -10.892.000 37.19%
2003 11.267.000 196.67%
2004 14.132.000 20.27%
2005 -4.260.000 431.74%
2006 -11.266.000 62.19%
2007 3.704.000 404.16%
2008 -91.630.000 104.04%
2009 16.138.000 667.79%
2010 -119.759.000 113.48%
2011 19.831.000 703.9%
2012 20.437.000 2.97%
2013 -16.180.000 226.31%
2014 20.941.000 177.26%
2015 41.228.000 49.21%
2016 705.000 -5747.94%
2017 43.131.000 98.37%
2018 11.759.000 -266.79%
2019 130.521.000 90.99%
2020 -71.917.000 281.49%
2021 18.675.000 485.1%
2022 -68.281.000 127.35%
2023 -50.848.000 -34.28%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Surgalign Holdings, Inc. Gross Profit
Year Gross Profit Growth
1999 14.429.683
2000 31.221.000 53.78%
2001 28.095.000 -11.13%
2002 24.181.000 -16.19%
2003 32.744.000 26.15%
2004 37.177.000 11.92%
2005 19.742.000 -88.31%
2006 19.323.000 -2.17%
2007 37.650.000 48.68%
2008 68.814.000 45.29%
2009 77.493.000 11.2%
2010 76.003.000 -1.96%
2011 77.214.000 1.57%
2012 85.217.000 9.39%
2013 80.105.000 -6.38%
2014 133.797.000 40.13%
2015 149.742.000 10.65%
2016 132.349.000 -13.14%
2017 142.521.000 7.14%
2018 140.123.000 -1.71%
2019 84.646.000 -65.54%
2020 57.747.000 -46.58%
2021 60.725.000 4.9%
2022 40.288.000 -50.73%
2023 42.696.000 5.64%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Surgalign Holdings, Inc. Net Profit
Year Net Profit Growth
1999 2.959.493
2000 4.459.000 33.63%
2001 -5.505.000 181%
2002 -13.505.000 59.24%
2003 6.356.000 312.48%
2004 6.155.000 -3.27%
2005 -5.551.000 210.88%
2006 -11.125.000 50.1%
2007 -2.096.000 -430.77%
2008 -99.978.000 97.9%
2009 5.855.000 1807.57%
2010 -129.399.000 104.52%
2011 8.378.000 1644.51%
2012 8.402.000 0.29%
2013 -17.814.000 147.17%
2014 2.696.000 760.76%
2015 14.915.000 81.92%
2016 -14.399.000 203.58%
2017 6.272.000 329.58%
2018 -1.250.000 601.76%
2019 -248.778.000 99.5%
2020 -194.195.000 -28.11%
2021 -122.906.000 -58%
2022 -54.605.000 -125.08%
2023 16.580.000 429.34%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Surgalign Holdings, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1999 1
2000 0 0%
2001 0 0%
2002 -1 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 -2 100%
2009 0 0%
2010 -2 100%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 -106 100%
2020 -78 -35.9%
2021 -30 -160%
2022 -8 -275%
2023 2 500%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Surgalign Holdings, Inc. Free Cashflow
Year Free Cashflow Growth
1999 -9.340.878
2000 -19.291.000 51.58%
2001 -27.577.000 30.05%
2002 -9.192.000 -200.01%
2003 -3.575.000 -157.12%
2004 -5.690.000 37.17%
2005 -7.280.000 21.84%
2006 -8.071.000 9.8%
2007 4.889.000 265.08%
2008 -7.446.000 165.66%
2009 -9.183.000 18.92%
2010 22.333.000 141.12%
2011 19.283.000 -15.82%
2012 5.942.000 -224.52%
2013 -20.380.000 129.16%
2014 -9.420.000 -116.35%
2015 -9.242.000 -1.93%
2016 -2.629.000 -251.54%
2017 -12.112.000 78.29%
2018 2.037.000 694.6%
2019 -25.889.000 107.87%
2020 -102.076.000 74.64%
2021 -65.864.000 -54.98%
2022 -59.365.000 -10.95%
2023 -10.354.000 -473.35%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Surgalign Holdings, Inc. Operating Cashflow
Year Operating Cashflow Growth
1999 -6.475.345
2000 -9.213.000 29.72%
2001 -4.394.000 -109.67%
2002 6.466.000 167.96%
2003 -1.898.000 440.67%
2004 -2.869.000 33.84%
2005 -1.681.000 -70.67%
2006 -6.743.000 75.07%
2007 7.062.000 195.48%
2008 -631.000 1219.18%
2009 -4.374.000 85.57%
2010 29.389.000 114.88%
2011 27.767.000 -5.84%
2012 20.803.000 -33.48%
2013 -4.454.000 567.06%
2014 6.894.000 164.61%
2015 8.996.000 23.37%
2016 15.323.000 41.29%
2017 2.455.000 -524.15%
2018 16.774.000 85.36%
2019 -9.456.000 277.39%
2020 -88.038.000 89.26%
2021 -51.792.000 -69.98%
2022 -52.109.000 0.61%
2023 -9.022.000 -477.58%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Surgalign Holdings, Inc. Capital Expenditure
Year Capital Expenditure Growth
1999 2.865.533
2000 10.078.000 71.57%
2001 23.183.000 56.53%
2002 15.658.000 -48.06%
2003 1.677.000 -833.69%
2004 2.821.000 40.55%
2005 5.599.000 49.62%
2006 1.328.000 -321.61%
2007 2.173.000 38.89%
2008 6.815.000 68.11%
2009 4.809.000 -41.71%
2010 7.056.000 31.85%
2011 8.484.000 16.83%
2012 14.861.000 42.91%
2013 15.926.000 6.69%
2014 16.314.000 2.38%
2015 18.238.000 10.55%
2016 17.952.000 -1.59%
2017 14.567.000 -23.24%
2018 14.737.000 1.15%
2019 16.433.000 10.32%
2020 14.038.000 -17.06%
2021 14.072.000 0.24%
2022 7.256.000 -93.94%
2023 1.332.000 -444.74%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Surgalign Holdings, Inc. Equity
Year Equity Growth
1999 15.437.309
2000 72.476.000 78.7%
2001 67.784.000 -6.92%
2002 82.622.000 17.96%
2003 92.397.000 10.58%
2004 99.602.000 7.23%
2005 117.813.000 15.46%
2006 109.890.000 -7.21%
2007 111.643.000 1.57%
2008 281.050.000 60.28%
2009 289.889.000 3.05%
2010 161.936.000 -79.01%
2011 172.419.000 6.08%
2012 183.992.000 6.29%
2013 168.053.000 -9.48%
2014 167.835.000 -0.13%
2015 181.356.000 7.46%
2016 164.916.000 -9.97%
2017 181.737.000 9.26%
2018 183.624.000 1.03%
2019 34.564.000 -431.26%
2020 24.170.000 -43%
2021 8.237.000 -193.43%
2022 -25.729.000 132.01%
2023 -18.935.000 -35.88%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Surgalign Holdings, Inc. Assets
Year Assets Growth
1999 48.538.314
2000 108.911.000 55.43%
2001 118.700.000 8.25%
2002 141.190.000 15.93%
2003 136.416.000 -3.5%
2004 124.730.000 -9.37%
2005 142.262.000 12.32%
2006 129.808.000 -9.59%
2007 135.966.000 4.53%
2008 334.080.000 59.3%
2009 354.507.000 5.76%
2010 225.758.000 -57.03%
2011 230.027.000 1.86%
2012 241.409.000 4.71%
2013 369.854.000 34.73%
2014 378.135.000 2.19%
2015 381.065.000 0.77%
2016 368.031.000 -3.54%
2017 345.906.000 -6.4%
2018 361.186.000 4.23%
2019 344.509.000 -4.84%
2020 122.704.000 -180.76%
2021 123.799.000 0.88%
2022 70.242.000 -76.25%
2023 67.712.000 -3.74%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Surgalign Holdings, Inc. Liabilities
Year Liabilities Growth
1999 33.101.005
2000 36.435.000 9.15%
2001 50.153.000 27.35%
2002 58.568.000 14.37%
2003 44.019.000 -33.05%
2004 25.128.000 -75.18%
2005 24.449.000 -2.78%
2006 19.918.000 -22.75%
2007 24.323.000 18.11%
2008 53.030.000 54.13%
2009 64.618.000 17.93%
2010 63.822.000 -1.25%
2011 57.608.000 -10.79%
2012 57.417.000 -0.33%
2013 201.801.000 71.55%
2014 210.300.000 4.04%
2015 199.709.000 -5.3%
2016 203.115.000 1.68%
2017 164.169.000 -23.72%
2018 177.562.000 7.54%
2019 309.945.000 42.71%
2020 98.534.000 -214.56%
2021 115.562.000 14.73%
2022 95.971.000 -20.41%
2023 86.647.000 -10.76%

Surgalign Holdings, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
4.32
Net Income per Share
-3.36
Price to Earning Ratio
-0.05x
Price To Sales Ratio
0.03x
POCF Ratio
-0.08
PFCF Ratio
-0.05
Price to Book Ratio
-0.13
EV to Sales
-0.18
EV Over EBITDA
0.2
EV to Operating CashFlow
0.37
EV to FreeCashFlow
0.31
Earnings Yield
-18.39
FreeCashFlow Yield
-20.3
Market Cap
0,00 Bil.
Enterprise Value
-0,01 Bil.
Graham Number
10.37
Graham NetNet
-3.54

Income Statement Metrics

Net Income per Share
-3.36
Income Quality
0.64
ROE
4.16
Return On Assets
-0.66
Return On Capital Employed
-1.54
Net Income per EBT
0.97
EBT Per Ebit
0.62
Ebit per Revenue
-1.28
Effective Tax Rate
0.03

Margins

Sales, General, & Administrative to Revenue
1.17
Research & Developement to Revenue
0.18
Stock Based Compensation to Revenue
0.06
Gross Profit Margin
0.39
Operating Profit Margin
-1.28
Pretax Profit Margin
-0.8
Net Profit Margin
-0.78

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-2.16
Free CashFlow per Share
-2.56
Capex to Operating CashFlow
0.19
Capex to Revenue
-0.09
Capex to Depreciation
-3.58
Return on Invested Capital
8.26
Return on Tangible Assets
-0.66
Days Sales Outstanding
87.7
Days Payables Outstanding
78.26
Days of Inventory on Hand
141.34
Receivables Turnover
4.16
Payables Turnover
4.66
Inventory Turnover
2.58
Capex per Share
-0.4

Balance Sheet

Cash per Share
1,68
Book Value per Share
-1,42
Tangible Book Value per Share
-1.42
Shareholders Equity per Share
-1.42
Interest Debt per Share
0.83
Debt to Equity
-0.54
Debt to Assets
0.15
Net Debt to EBITDA
0.23
Current Ratio
2.67
Tangible Asset Value
-0,02 Bil.
Net Current Asset Value
-0,03 Bil.
Invested Capital
-0.54
Working Capital
0,03 Bil.
Intangibles to Total Assets
0
Average Receivables
0,01 Bil.
Average Payables
0,01 Bil.
Average Inventory
15620000
Debt to Market Cap
6.1

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Surgalign Holdings, Inc. Dividends
Year Dividends Growth

Surgalign Holdings, Inc. Profile

About Surgalign Holdings, Inc.

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spine implants worldwide. It offers products for thoracolumbar procedures, including Streamline TL Spinal Fixation system, a system for degenerative and complex spine procedures; and Streamline MIS Spinal Fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2.0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; and SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability. In addition, it develops Augmented Reality and Artificial Intelligence digital surgery platform to enable digital spine surgery. The company markets its products through independent spine and biomaterial distributors to hospitals, ambulatory surgery centers, and healthcare providers, as well as through direct sales force. The company was incorporated in 1997 and is headquartered in Deerfield, Illinois.

CEO
Mr. Terry M. Rich
Employee
217
Address
520 Lake Cook Road
Deerfield, 60015

Surgalign Holdings, Inc. Executives & BODs

Surgalign Holdings, Inc. Executives & BODs
# Name Age
1 Mr. William Scott Durall
Chief Commercial Officer
70
2 Mr. Bob Watkins
Chief Technology Officer
70
3 Mr. Terry M. Rich
Pres, Chief Executive Officer & Director
70
4 Mr. Enrico Sangiorgio
Executive Vice President of International
70
5 Mr. David B. Lyle
Chief Financial Officer
70
6 Mr. Christopher Thunander
Vice President & Chief Accounting Officer
70
7 Ms. Suzanne C. Zoumaras
Chief People Officer
70
8 Mr. Olivier M. Visa
Pres of Global OEM
70
9 Mr. Paolo G. Amoruso
Chief Legal Officer, Gen. Counsel & Corporation Sec.
70
10 Mr. John N. Varela
Executive Vice President of Global Operations
70
11 Mr. Bryan Cornwall
Executive Vice President of Research and Clinical Affairs
70
12 Mr. Marc MacKey
Executive Vice President of Digital Surgery
70
13 Dr. G. Bryan Cornwall P.Eng., Ph.D.
Executive Vice President of Research and Clinical Affairs
70

Surgalign Holdings, Inc. Competitors